Clinical trials: Metastatic Sarcoma, open to volunteers
Solid Tumor, Melanoma
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Melanoma, HNSCC, Sarcoma
- Trial name
- NCT04370587
- Testing
- T3011, T3011 + pembrolizumab
- Where
- 9 sites in United States, Australia
- Volunteers
- 30 people
- Sponsor
- ImmVira Pharma Co. Ltd
Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow.
- Conditions
- Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
- Trial name
- NCT06066138
- Testing
- Atezolizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma Metastatic, Locally Advanced Soft Tissue Sarcoma
Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment.
ePPS-2202 is a study designed to evaluate the benefits of a dematerialised personalised care plan (PCP) compared to standard information/PCP for patients with advanced sarcomas receiving systemic treatment.
- Trial name
- ePPS (NCT06211257)
- Testing
- Dematerialized Personalized Care Plan (ePCP)
- Where
- 11 sites in France
- Volunteers
- 377 people
- Sponsor
- Centre Oscar Lambret
Alveolar Soft Part Sarcoma, Leiomyosarcoma
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA.
- Conditions
- Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma
- Trial name
- APROMISS (NCT03016819)
- Testing
- AL3818, Dacarbazine, Midazolam 2 mg for CYP3A4 phenotyping
- Where
- 24 sites in United States, China and 3 more
- Volunteers
- 325 people
- Sponsor
- Advenchen Laboratories, LLC
Soft Tissue Sarcomas, Angiosarcoma
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
This study will enroll patients with specific subtypes of unresectable or metastatic soft tissue sarcoma, and will combine tislelizumab with the standard chemotherapy of liposomal doxorubicin and ifosfamide to initially explore…
- Conditions
- Soft Tissue Sarcomas, Angiosarcoma, Fibrosarcoma, Leiomyosarcoma
- Trial name
- TAIS (NCT06849986)
- Testing
- Tislelizumab+liposomal doxorubicin+ifosfamide
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Fudan University
Osteosarcoma, Pulmonary Metastasis
Safety and Feasibility of Intraoperative Visualization With Cytalux in Children
Pediatric subjects aged 6-17 with biopsy confirmed cancer and imaging findings suspicious for pulmonary metastatic disease scheduled to undergo pulmonary metastasectomy via and open or minimally invasive approach.
- Conditions
- Osteosarcoma, Pulmonary Metastasis, Fluorescence, Metastatic Sarcoma
- Trial name
- Cytalux (NCT06235125)
- Testing
- Cytalux
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
PDAC
Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC
This is an open-label, multi-centre, single-arm Phase 1/2 clinical trial of the safety, expansion, persistence and clinical activity of a set of engineered autologous T cells products each capable of recognizing a specific…
- Trial name
- NCT07145450
- Testing
- ANOC-001 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles), ANOC-002 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles), ANOC-003 (TCR-T cells targeting KRAS G12D mutation presented by specific HLA alleles)
- Where
- 10 sites in Denmark, Germany and 2 more
- Volunteers
- 96 people
- Sponsor
- Anocca AB
Bone Neoplasms, Soft Tissue Neoplasms
Stress and Anxiety Before Biopsy, After Biopsy Results, and During Treatment in Patients With Suspected Bone or Soft Tissue Cancer
This prospective observational study will follow adults who are scheduled for a clinically indicated biopsy because of a suspected solid tumor involving bone or soft tissue.
- Conditions
- Bone Neoplasms, Soft Tissue Neoplasms, Anxiety, Stress, Psychological
- Trial name
- BIOPSY-STRESS (NCT07727434)
- Testing
- Routine Diagnostic and Treatment Pathway
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Istanbul University
Osteosarcoma, Osteosarcoma Metastatic
Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
In advanced osteosarcoma where traditional chemotherapy has failed, the multi-targeted tyrosine kinase inhibitor apatinib has become a mainstream systemic treatment option in China.
- Trial name
- NCT07479732
- Testing
- Liposomal Irinotecan, Apatinib in arm1
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Peking University People's Hospital
Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT05824975
- Testing
- GI-102 subcutaneous (SC), GI-102, doxorubicin
- Where
- 11 sites in United States, South Korea
- Volunteers
- 358 people
- Sponsor
- GI Innovation, Inc.
Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma
Ivonescimab in the Treatment of Multiple Advanced Tumors
The goal of this clinical trial is to learn if Ivonescimab works to treat advanced rare tumors including cohort 1: PAGET's disease of scrotum with infiltrating sweat gland carcinoma.
- Conditions
- Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma, Paget Disease, Extramammary, Renal Angiomyolipoma
- Trial name
- NCT06683846
- Testing
- Ivocizumab
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Fudan University
Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC)
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
This study will recruit patients with the following cancer indications: ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer, with inoperable locally advanced or metastatic solid tumours.
- Conditions
- Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC), Synovial Sarcomas, Head and Neck Cancer
- Trial name
- NCT07613723
- Testing
- ZI-MA4-1 (TCR-NK cells), Cyclophosphamide, Fludarabine
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people
- Sponsor
- Zelluna Immunotherapy AS
Soft Tissue Sarcoma
Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma
This is an open-label, randomized, phase II study to evaluate the clinical activity of pembrolizumab in combination with pazopanib compared to pazopanib monotherapy.
- Trial name
- NCT05679921
- Testing
- pembrolizumab, pazopanib
- Where
- South Korea
- Volunteers
- 116 people
- Sponsor
- Yonsei University
Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in…
- Conditions
- Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma, Metastatic Sarcoma
- Trial name
- NCT05711615
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 16 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
The main goal of this study is to test a new medicine, Risvutatug Rezetecan also called Ris-Rez. We want to see if this medicine can help people with certain types of cancer, whether its safe to use, how well people tolerate it…
- Trial name
- NCT07602777
- Testing
- Ris-Rez, G-CSF
- Where
- 13 sites in United States, Canada and 4 more
- Volunteers
- 64 people
- Sponsor
- GlaxoSmithKline
Leiomyosarcoma of Ovary, Soft Tissue Sarcoma
Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
Study is aimed at evaluating the activity of Trabectedin (arm A) in advanced leiomyosarcomas, having Gemcitabine (arm B) as the comparator.
- Trial name
- ISG-ARTICLE (NCT04383119)
- Testing
- Trabectedin, Gemcitabine, No Intervention: Observational Cohort
- Where
- 17 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Italian Sarcoma Group
Bone Sarcomas
A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
To study the treatment efficacy of zanzalintinib monotherapy in patients with advanced and/or metastatic bone sarcomas.
- Trial name
- NCT07193550
- Testing
- Zanzalintinib
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat…
- Trial name
- NCT06345729
- Testing
- Calderasib, Pembrolizumab
- Where
- 246 sites in United States, Argentina and 28 more
- Volunteers
- 348 people
- Sponsor
- Merck Sharp & Dohme LLC
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT03889899
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Alpha Tau Medical LTD.
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska